1153 ET - Praxis Precision Medicines is still a buy despite the late-stage study setback for ulixacaltamide in essential tremor, analysts at Truist say. In a research note, Truist says it still likes Praxis for vormatrigine in focal onset seizures and relutrigine in developmental and epileptic epilepsies, which the firm says puts a floor on the stock. Truist removes essential tremor from its Praxis valuation, which drops its price target on the stock to $85 from $175. Praxis down 40% to $39.26. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
February 28, 2025 11:53 ET (16:53 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.